title: Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
authors.affiliation: a The University of Chicago Medical Center , Chicago , IL , USA.
authors.forename: Natalie
authors.initials: N
authors.lastname: Galanina
authors.affiliation: b North Shore University Health System , Chicago , IL , USA.
authors.forename: Jagoda
authors.initials: J
authors.lastname: Jasielec
authors.affiliation: c The University of Illinois at Chicago , Chicago , IL , USA.
authors.forename: David
authors.initials: D
authors.lastname: Peace
authors.affiliation: a The University of Chicago Medical Center , Chicago , IL , USA.
authors.forename: Sonali M
authors.initials: SM
authors.lastname: Smith
authors.affiliation: a The University of Chicago Medical Center , Chicago , IL , USA.
authors.forename: Chadi
authors.initials: C
authors.lastname: Nabhan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C527517:ofatumumab